Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is primarily used as adjunctive therapy for seizures.
## Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
* Off-label use for other seizure types (e.g., absence, myoclonic, atonic seizures) may be considered based on clinical judgment and evidence.
## Adult Dosing
* **Initial Dose:** 5 mg twice daily.
* **Titration:** Increase dose gradually as tolerated, typically by 5 mg every week.
* **Maintenance Dose:** Typically 10 mg to 20 mg twice daily.
* **Maximum Dose:** 20 mg twice daily (40 mg/day). Some sources suggest a higher maximum of 30 mg twice daily (60 mg/day) for specific refractory epilepsy cases under specialist supervision.
## Pediatric Dosing
* **Lennox-Gastaut Syndrome (2 to 18 years):**
* **Initial Dose:** 5 mg twice daily.
* **Titration:** Increase dose gradually as tolerated, typically by 5 mg every week.
* **Maintenance Dose:** Typically 5 mg to 10 mg twice daily.
* **Maximum Dose:** 10 mg twice daily (20 mg/day).
## Dose Adjustments
* **Hepatic Impairment:** Use with caution; dose reduction may be necessary due to reduced clearance.
* **Renal Impairment:** No specific dose adjustment is recommended, but monitor closely for adverse effects.
* **Concomitant Medications:**
* **Strong CYP3A4 Inhibitors:** May increase clobazam levels; consider dose reduction.
* **Strong CYP3A4 Inducers:** May decrease clobazam levels; consider dose increase.
* **CNS Depressants:** Additive sedative effects; use caution and consider dose reduction.
* **Valproic Acid:** Monitor for potential increase in valproic acid levels and signs of valproic acid toxicity (e.g., hyperammonemia).
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
* Severe hepatic insufficiency.
* Myasthenia gravis.
* Sleep apnea.
## Adverse Effects
* **Common:** Drowsiness, somnolence, fatigue, lethargy, ataxia, drooling, constipation, insomnia, agitation, aggressive behavior, respiratory depression.
* **Serious:** Suicidal ideation/behavior, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), withdrawal symptoms upon abrupt discontinuation, paradoxical reactions (e.g., excitement, hostility), dependence, abuse potential.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Increased risk of sedation and respiratory depression.
* **CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir):** Can increase clobazam concentrations.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine):** Can decrease clobazam concentrations.
* **Valproic Acid:** Increased risk of valproic acid-associated hyperammonemia and encephalopathy.
* **Phenytoin:** Clobazam can increase phenytoin levels.
## Monitoring
* Seizure frequency and severity.
* Signs of central nervous system (CNS) depression (drowsiness, fatigue, coordination).
* Behavioral changes, including suicidal ideation.
* Signs of withdrawal upon dose reduction or discontinuation.
* Liver function tests may be considered, especially with long-term use or in patients with hepatic impairment.
* Valproic acid levels if co-administered.
## Clinical Pearls
* Clobazam has a longer half-life compared to many other benzodiazepines, allowing for once or twice-daily dosing.
* Abrupt discontinuation can precipitate withdrawal symptoms, including seizures. Tapering is recommended.
* Due to the risk of serious skin reactions, patients should be advised to seek immediate medical attention if they develop a rash, blistering, or peeling skin.
* Clobazam is an FDA-approved medication for adjunctive treatment of LGS in children 2 years and older.
***
*This information is intended for clinical use and does not replace professional medical advice. Always consult the most current prescribing information and relevant guidelines before making treatment decisions.*
